Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
29.38
-0.11 (-0.37%)
Feb 27, 2026, 4:00 PM EST - Market closed
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
$495,448
Profits / Employee
-$2,395,811
Market Cap
2.80B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 739 |
| Adaptive Biotechnologies | 619 |
| Beam Therapeutics | 511 |
| Travere Therapeutics | 385 |
| Wave Life Sciences | 288 |
| Dyne Therapeutics | 240 |
| Vera Therapeutics | 224 |
| Catalyst Pharmaceuticals | 181 |
VRDN News
- 2 days ago - Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 7 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 2 months ago - Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
- 2 months ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 4 months ago - Viridian Therapeutics Is Ready For An Eventful 2026 - Seeking Alpha
- 4 months ago - Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
- 4 months ago - Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - Business Wire